Viral Decay Rates are Similar in HIV-infected Patients with and without TB Coinfection during Treatment with an Efavirenz-based Regimen | Zendy

Margaret Lartey | Zendy; Kwamena W. Sagoe | Zendy; Hongmei Yang | Zendy; Ernest Kenu | Zendy; Fafa Xexemeku | Zendy; Joseph OliverCommey | Zendy; Vincent Boima | Zendy; Makafui Seshie | Zendy; A. Sagoe | Zendy; J. A. A. Mingle | Zendy; Timothy Flanigan | Zendy; Huaiqing Wu | Zendy; Awewura Kwara | Zendy

Open Access

Viral Decay Rates are Similar in HIV-infected Patients with and without TB Coinfection during Treatment with an Efavirenz-based Regimen

Author(s) -

Margaret Lartey,

Kwamena W. Sagoe,

Hongmei Yang,

Ernest Kenu,

Fafa Xexemeku,

Joseph OliverCommey,

Vincent Boima,

Makafui Seshie,

A. Sagoe,

J. A. A. Mingle,

Timothy Flanigan,

Huaiqing Wu,

Awewura Kwara

Publication year - 2011

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciq196

Subject(s) - efavirenz , coinfection , medicine , regimen , tuberculosis , virology , human immunodeficiency virus (hiv) , viral load , antiretroviral therapy , sida , pharmacotherapy , viral disease , pathology

Viral decay rates during efavirenz-based therapy were compared between human immunodeficiency virus (HIV)-infected patients without tuberculosis (n = 40) and those with tuberculosis coinfection who were receiving concurrent antituberculous therapy (n = 34). Phase I and II viral decay rates were similar in the 2 groups (P > .05). Overall, concurrent antituberculous therapy did not reduce the efficacy of the HIV treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research